Phase II Study of Docetaxel, Cisplatin and 5-Fluorouracil (DCF) for Metastatic Esophageal Cancer
Anticancer Research, 04/10/2012Tamura S et al.
This DCF regimen was well tolerated; the results of this study provide information on the potential of docetaxel, cisplatin and 5–fluorouracil (DCF) for treatment of patients with metastatic squamous cell carcinoma of the esophagus (SCCE).
Eligible patients included those with previously untreated SCCE, score of ECOG 0-2 and adequate organ function.
Patients received 60 mg/m2 docetaxel and 70 mg/m2 cisplatin on day 1, and 600 mg/m2 5-fluorouracil on days 1-5 every four weeks.
Twenty-nine (22 male, 7 female) patients with metastatic SCCE (M1a: 20, M1b: 9) were enrolled.
Three cases achieved complete response and seven a partial response.
In addition to these patients, three patients achieved good response and underwent surgical resection, giving an overall response rate of 34.5% (95% Confidene Interval=17.9-54.3) in confirmed cases and 44.8% (95% CI=26.4-64.3) in unconfirmed cases.
Grade 3 or 4 hematological toxicities were as follows: leukopenia in 15 patients (52%), neutropenia in 22 patients (76%) and febrile neutropenia in 6 patients (21%), while grade 3 or 4 non-hematological toxicities were relatively rare.
MDLinx connects healthcare professionals and patients to tomorrow's important medical news, while providing the pharmaceutical and healthcare industries with highly targeted interactive marketing, education, content, and medical research solutions.